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Osteocytic oxygen sensing controls bone mass
through epigenetic regulation of sclerostin
Steve Stegen1, Ingrid Stockmans1, Karen Moermans1, Bernard Thienpont 2, Patrick H. Maxwell3,
Peter Carmeliet4,5 & Geert Carmeliet 1
Preservation of bone mass is crucial for healthy ageing and largely depends on adequate
responses of matrix-embedded osteocytes. These cells control bone formation and resorption
concurrently by secreting the WNT/β-catenin antagonist sclerostin (SOST). Osteocytes
reside within a low oxygen microenvironment, but whether and how oxygen sensing reg-
ulates their function remains elusive. Here, we show that conditional deletion of the oxygen
sensor prolyl hydroxylase (PHD) 2 in osteocytes results in a high bone mass phenotype,
which is caused by increased bone formation and decreased resorption. Mechanistically,
enhanced HIF-1α signalling increases Sirtuin 1-dependent deacetylation of the Sost promoter,
resulting in decreased sclerostin expression and enhanced WNT/β-catenin signalling.
Additionally, genetic ablation of PHD2 in osteocytes blunts osteoporotic bone loss induced by
oestrogen deficiency or mechanical unloading. Thus, oxygen sensing by PHD2 in osteocytes
negatively regulates bone mass through epigenetic regulation of sclerostin and targeting
PHD2 elicits an osteo-anabolic response in osteoporotic models.
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Bone needs to be continuously remodelled throughout life tomaintain optimal quality and strength. This processrequires a strict balance between the activities of bone-
forming osteoblasts and bone-resorbing osteoclasts to avoid bone
loss1. Recent findings show that terminally differentiated matrix-
embedded osteocytes are crucial in the regulation of bone
remodelling, because they can control both osteoblast and
osteoclast differentiation and function2–6. An important factor in
the communication of osteocytes with osteoblasts and osteoclasts
is sclerostin, a secreted WNT/β-catenin antagonist encoded by
the Sost gene7,8. Genetic evidence shows that increased sclerostin
levels result in decreased bone formation and increased bone
resorption9–15, suggesting that factors regulating sclerostin
expression are likely as critical for bone homoeostasis.
The control of bone remodelling by osteocytes is influenced by
endocrine and paracrine factors such as parathyroid hormone
and WNTs4–6, but possibly also by the local environment. Indeed,
osteocytes embedded in the cortical bone matrix are exposed to
low oxygen tensions16, but whether osteocytic oxygen sensing is
involved in the control of bone homoeostasis is still unknown. In
general, cells can respond to hypoxia by an elegant pathway
consisting of prolyl hydroxylases (PHDs) that detect fluctuations
in oxygen tension and regulate the abundance of the hypoxia-
inducible transcription factor HIF-α, which is considered as the
effector of the hypoxia response. When oxygen levels fall below a
critical threshold, PHD activity is diminished, resulting in HIF
stabilization, which induces transcription of genes involved in
diverse physiological processes ranging from angiogenesis to
metabolism to matrix synthesis17–19. In fact, in vivo oxygen
tensions in osteocyte lacunae are reported to be well below 10%16,
a critical threshold for PHD enzyme activity in vitro20,21, sug-
gesting that stringent regulation of HIF signalling may be
necessary for proper osteocyte functioning.
We and others have already shown that enhanced HIF sig-
nalling in osteoprogenitors and osteoblasts increases bone mass
during development, homoeostasis, regeneration and pathol-
ogy22–28, and that the opposite phenotype is found when Hif-1α
is deleted in osteolineage cells22,29,30. The high bone mass phe-
notype is explained by increased angiogenesis or a metabolic shift
to glycolysis, although detailed understanding of the bone ana-
bolic response is still lacking. In addition, some recent studies
show that PHD activity in osteoprogenitors is involved in the
HIF-induced increase in bone mass, although the contribution of
the different PHDs and the underlying mechanism are not fully
elucidated yet: constitutive combined deletion of Phd2 and Phd3
resulted in HIF-2α stabilization and decreased osteoclastogen-
esis26, whereas inducible deletion of Phd2 was sufficient to
increase bone mass, although the mechanism was not further
investigated27,28. Given the importance of osteocyte function for
bone metabolism and the fact that they reside in a low oxygen
environment, we hypothesized that oxygen sensing in osteocytes
controls bone homoeostasis and may interfere with pathological
bone loss.
We therefore investigated whether and how PHD oxygen
sensors control bone mass by generating mice with osteocyte-
specific genetic ablation of PHD2, the most abundantly expressed
isoform. We discovered that osteocytic deletion of PHD2 controls
bone formation and resorption through a Sirtuin 1 (SIRT1)-
dependent decrease in sclerostin expression resulting in increased
WNT/β-catenin signalling. Moreover, mice lacking PHD2 in
osteocytes are protected from disuse- and oestrogen deficiency-
induced bone loss, suggesting that therapeutic targeting of PHD2
can potentially be used for the treatment of osteoporosis.
Results
Osteocyte-specific PHD2 deletion increases bone mass. To
explore whether the oxygen sensor PHD2 is critical for osteocyte
function, we crossed Phd2fl/fl mice with Dentin Matrix Protein 1
(Dmp1)-Cre transgenic mice (Phd2ot−) resulting in very efficient
and specific deletion (Fig. 1a and Supplementary Fig. 1a-c). Of
note, Phd2 was highly expressed in osteocytes compared to other
osteogenic cells (Supplementary Fig. 1a, b), underscoring the
importance of the oxygen sensing machinery in osteocytes. Yet,
oxygen levels seem still adequate, as activation of hypoxia
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Fig. 1 Deletion of PHD2 in osteocytes increases bone mass. a PHD2 and β-actin immunoblot on whole-cell extracts isolated from osteocyte-enriched bone
fractions of 8-week-old mice. Results are representative of three experiments. b HIF-1α, HIF-2α and Lamin A/C immunoblot on nuclear cell extracts
isolated from osteocyte-enriched bone fractions. Results are representative of three experiments. c, d 3D microCT models (c) of the tibial metaphysis and
quantification (d) of trabecular bone volume (BV/TV) and cortical thickness (Ct.Th) in 8-week-old mice (n= 8 Phd2ot+–10 Phd2ot−). e, f Von Kossa
staining (e) of tibiae with quantification (f) of trabecular bone volume (BV/TV) (n= 8 Phd2ot+–10 Phd2ot−). Scale bar is 500 µm. Data are means ± SEM.
*p < 0.05 vs. Phd2ot+, **p < 0.01 vs. Phd2ot+ (Student′s t-test)
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signalling was largely absent in Phd2ot+ mice, evidenced by the
low number of HIF-1α-positive nuclei (Supplementary Fig. 1d).
Deficiency of PHD2 resulted in increased nuclear accumulation
of HIF-1α, but not HIF-2α (Fig. 1b and Supplementary Fig. 1d).
Phd2ot- mice were viable and undistinguishable from control
littermates at birth, and showed normal growth, as body weight
and tibia length were comparable to control mice at 8 weeks of
age (Supplementary Fig. 1e, f). Of note, we could not observe any
sign of erythrocytosis (Supplementary Fig. 1g–j), which has been
previously reported when HIF signalling was induced in
osteoblasts31.
Deletion of PHD2 in osteocytes increased bone mass with 40%
in 3-week-old male and female mice (Supplementary
Fig. 2a, b) and this increase in trabecular and cortical bone
volume became more pronounced in adult mice and was
preserved with ageing, as analysed by ex vivo micro-computed
tomography (microCT) and histomorphometry on Von Kossa-
stained sections (Fig. 1c–f and Supplementary Fig. 2a, b). In
correspondence with the enhanced bone mass, bone strength was
increased in Phd2ot− mice, as evidenced by three-point bending
tests (Supplementary Fig. 2c–f). Thus, deletion of PHD2 in
osteocytes causes an increase in bone mass, indicating that bone
formation exceeded resorption.
Bone formation exceeds bone resorption in Phd2ot− mice. To
investigate the cellular mechanisms responsible for the high bone
mass phenotype of Phd2ot− mice, we first analysed bone
formation parameters. Histomorphometry of H&E-stained sec-
tions revealed an increase in the number and surface of cuboidal
osteoblasts lining the trabeculae (Fig. 2a, b) and in the density of
viable osteocytes in the cortical bone of 8-week-old male Phd2ot−
mice (Fig. 2c, d). In addition, we observed enhanced osteoblast
activity in Phd2ot− mice, evidenced by an increase in the thick-
ness of unmineralized matrix (osteoid) and in its mineralization,
as analysed by Goldner staining (Supplementary Fig. 3a, b) and
in vivo calcein labelling (Fig. 2e, f), respectively. Consistent with
these observations, we found an increase in serum osteocalcin
levels (Fig. 2g) and femoral transcript levels of osteoblast markers
including runt-related transcription factor 2 (Runx2), collagen
type I (Col1) and osteocalcin (Ocn) in Phd2ot− mice (Supple-
mentary Fig. 3c).
In addition, we noticed that silencing PHD2 in osteocytes also
decreased bone resorption. Histomorphometric analysis of
TRAP-stained sections revealed a reduction in osteoclast surface
in mutant mice (Fig. 2h, i), and the decrease in serum collagen
type I cross-linked C-telopeptide (CTx-I) levels underscores the
reduction in osteoclast activity (Fig. 2j). Interestingly, hemato-
poietic bone marrow cells of Phd2ot− mice were able to
differentiate properly to osteoclasts in vitro (Supplementary
Fig. 3d, e), suggesting that the decrease in bone resorption is due
to a cell non-autonomous effect. Taken together, silencing PHD2
in osteocytes causes a high bone mass phenotype, resulting from
the combination of increased bone formation and decreased bone
resorption.
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Fig. 2 Bone formation exceeds bone resorption in Phd2ot− mice. a, b H&E staining (a) of the tibial metaphysis with quantification (b) of osteoblast number
per bone surface (N.Ob/B.S) and osteoblast surface per bone surface (Ob.S/B.S) in 8-week-old mice (n= 8 Phd2ot+–10 Phd2ot−). White arrowheads in
a indicate osteoblasts. c, d H&E staining (c) of the cortical diaphysis of tibiae with quantification (d) of osteocyte number per bone area (N.Ot/B.Ar) and
percentage of empty osteocyte lacunae (n= 8 Phd2ot+–10 Phd2ot−). e, f Calcein labelling of mineralizing surfaces on trabeculae (e) with quantification
(f) of the bone formation rate (BFR) and mineral apposition rate (MAR) (n= 8 Phd2ot+–10 Phd2ot−). White arrowheads in e indicate calcein incorporation.
g Serum osteocalcin levels (n= 8 Phd2ot+–10 Phd2ot−). h, i TRAP staining (h) of the tibial metaphysis with quantification (i) of osteoclast surface per bone
surface (Oc.S/B.S) (n= 8 Phd2ot+–10 Phd2ot−). Black arrowheads in h indicate osteoclasts. j Serum CTx-I levels (n= 8 Phd2ot+ –10 Phd2ot-). Data are
means ± SEM. *p < 0.05 vs. Phd2ot+, **p < 0.01 vs. Phd2ot+, N.S. is not significant (Student′s t-test). Scale bars in a, e and h are 50 µm, scale bar in c is
100 µm
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PHD2 deletion decreases sclerostin expression through SIRT1.
The opposite changes in bone formation and bone resorption
elicited by PHD2 deletion in osteocytes suggested the involve-
ment of sclerostin, a WNT/β-catenin inhibitor. Indeed, sclerostin
mRNA and protein levels were decreased in osteocytes of Phd2ot−
long bones (Fig. 3a, b and Supplementary Fig. 4a), whereas other
osteocyte-specific factors, including DMP1 and metalloendo-
peptidase homolog PEX (PHEX), were not altered (Fig. 3a). The
reduced sclerostin expression resulted in activation of WNT/β-
catenin signalling evidenced by increased nuclear accumulation of
the non-phosphorylated, active form of β-catenin in osteocytes
(Fig. 3c), and enhanced expression of WNT/β-catenin target
genes including Axin-2 (Axin2), Dickkopf-4 (Dkk-4), lymphoid
enhancer-binding factor 1 (Lef-1) and T-cell factor 1 (Tcf-1)
(Fig. 3d). Of note, total cytoplasmic β-catenin levels were com-
parable between genotypes (Fig. 3c).
To decipher the molecular pathway upstream of decreased Sost
transcription in Phd2ot− mice, we hypothesized that epigenetic
regulation via SIRT1, a class III histone deacetylase (HDAC)
could be involved. This assumption was based on two unrelated
published observations showing that HIF signalling increases
SIRT1 expression32 and that SIRT1 directly and negatively
regulates Sost expression in osteogenic cells in vivo33,34. However,
a link between HIF-1α, SIRT1 and sclerostin has not been shown
yet. We found that gene and protein expression of SIRT1 was
increased in PHD2-deficient osteocytes in vivo (Fig. 3e and
Supplementary Fig. 4b, c), whereas mRNA levels of other SIRT
isoforms were not changed (Supplementary Fig. 4c). A similar
effect was observed when the immortalized osteocyte cell line
IDG-SW3 was treated with the PHD inhibitor IOX2 (IDGIOX2),
which was added to the culture medium when these cells started
to express DMP1 during differentiation. This treatment increased
HIF-1α and SIRT1 levels, accompanied by decreased mRNA and
protein levels of sclerostin and increased WNT/β-catenin
signalling (Fig. 3f and Supplementary Fig. 4d–i). Moreover,
ChIP-qPCR analysis in IDGIOX2 cells showed a significant
enrichment of SIRT1 binding to specific regions in the Sost
promoter (Supplementary Fig. 5a), and a marked decrease in
histone 3 lysine 9 (H3K9) acetylation at these interrogated Sost
promoter regions (highest at 998–1115 bp upstream of the start
codon, region 1; Supplementary Fig. 5b), indicating epigenetic
control of Sost expression. To prove a causative link between
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Fig. 3 PHD2 deletion reduces sclerostin expression through SIRT1. a Phex, Dmp1 and Sost mRNA levels in osteocyte-enriched bone fractions of 8-week-old
mice (n= 8 Phd2ot+–10 Phd2ot−). b Sclerostin and β-actin immunoblot on whole-cell extracts isolated from osteocyte-enriched bone fractions. c Non-
phosphorylated (non-phospho) β-catenin and Lamin A/C immunoblot (nuclear cell extracts), and total β-catenin and β-actin immunoblot (whole-cell
extracts). Protein extracts are isolated from osteocyte-enriched bone fractions. d Axin2, Dkk-4, Lef-1 and Tcf-1 mRNA levels in osteocyte-enriched bone
fractions (n= 8 Phd2ot+– 10 Phd2ot−). e Sirtuin 1 and Lamin A/C immunoblot on nuclear cell extracts isolated from osteocyte-enriched bone fractions.
f Sirtuin 1, non-phospho β-catenin, Lamin A/C, sclerostin and β-actin immunoblot isolated from vehicle (IDGVEH) or IOX2-treated IDG-SW3 (IDGIOX2)
cells after 14 days of osteogenic differentiation. IDGVEH cells were treated with vehicle (−) or SRT1720 (SRT); IDGIOX2 cells were treated with vehicle (−)
or EX527 (EX). g Sirtuin 1, non-phospho β-catenin and Lamin A/C immunoblot on nuclear cell extracts isolated from IDGVEH or IDGIOX2 cells after 14 days
of osteogenic differentiation in the presence of recombinant sclerostin. Cells were treated as in f. Data are means ± SEM. Immunoblot images are
representative of three experiments. *p < 0.05 vs. Phd2ot+, **p < 0.01 vs. Phd2ot+ (Student′s t-test)
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HIF-SIRT1-Sost-β-catenin, we used two approaches. First, to
substantiate that SIRT1 action mediated the effect of HIF
signalling on Sost expression, we treated IDGIOX2 cells with
EX527, a potent and specific SIRT1 inhibitor. This treatment had
no effect on SIRT1 levels, nor on SIRT1 binding to the Sost
promoter, but caused a marked increase in H3K9 acetylation at
the Sost promoter resulting in higher mRNA and protein levels of
sclerostin (Fig. 3f and Supplementary Figs. 4d, e and 5c, d) and
decreased WNT/β-catenin signalling (Fig. 3f and Supplementary
Fig. 4f–i). Of note, culturing vehicle-treated IDG-SW3 cells
(IDGVEH) in the presence of the SIRT1 activator SRT1720 had
opposite effects and underlined the role of SIRT1 activity in
regulating Sost transcription (Fig. 3f and Supplementary Fig. 4d–i
and 5c, d). Second, to exclude that activation of WNT/β-catenin
signalling resulted from direct SIRT1-mediated deacetylation of
β-catenin35, we added recombinant sclerostin, an approach that
would only reverse the increased non-phosphorylated β-catenin
levels when they were caused by decreased Sost expression. In line
with this hypothesis, adding sclerostin to the culture medium of
IDGIOX2 or SRT1720-treated IDGVEH cells inhibited the increase
in active β-catenin levels (Fig. 3g). These data indicate that
inhibition of PHDs in osteocytes increases SIRT1 expression,
which modifies H3K9 acetylation of the Sost promoter and
consequently suppresses its transcription, resulting in increased
β-catenin activity.
Decreased sclerostin affects osteoblasts and osteoclasts. Next,
we investigated the cellular effects of this enhanced WNT/β-
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Fig. 4 Decreased sclerostin affects osteoblasts and osteoclasts. a Alizarin Red staining of IDGVEH or IDGIOX2 cells after 14 or 21 days of osteogenic
differentiation (n= 3). IDGVEH cells were treated with vehicle (−) or SRT1720 (SRT); IDGIOX2 cells were treated with vehicle (−) or EX527 (EX). b Alizarin
Red staining of IDGVEH or IDGIOX2 cells after 14 days of osteogenic differentiation in the presence of recombinant sclerostin (n= 3). Cells were treated as
in a. c Rankl and Opg mRNA levels in osteocyte-enriched bone fractions of 8-week-old mice (n= 8 Phd2ot+–10 Phd2ot-). d RANKL, OPG and β-actin
immunoblot on whole-cell extracts isolated from osteocyte-enriched bone fractions. e RANKL, OPG and β-actin immunoblot on whole-cell extracts isolated
from IDGVEH or IDGIOX2 cells after 14 days of osteogenic differentiation. Cells were treated as in a. f Quantification of TRAP-positive multinuclear cells
(MNC), formed after co-culturing wild-type hematopoietic cells with IDG-SW3 cells, in which Phd2 was deleted or not via CRISPR-Cas9 (n= 3). g Rankl/
OpgmRNA ratio in IDGVEH or IDGIOX2 cells after 14 days of osteogenic differentiation in the presence of recombinant sclerostin (n= 3). Cells were treated
as in a. Data are means ± SEM. Immunoblot images are representative of three experiments. *p < 0.05 vs. Phd2ot+ (Student′s t-test), #p < 0.05 (two-way
ANOVA)
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catenin signalling. IDGIOX2 cells showed enhanced osteogenic
differentiation capacity (Fig. 4a), as evidenced by Alizarin Red
staining. Consistent with the above-described molecular pathway,
the increase in osteogenic differentiation was blocked by inhi-
biting SIRT1 activity (Fig. 4a) or by adding recombinant scler-
ostin (Fig. 4b). Of note, treating IDGVEH cells with the SIRT
activator SRT1720 increased osteogenic differentiation (Fig. 4a),
which correlated with decreased sclerostin levels (Fig. 3f), and this
effect was reversed by adding sclerostin (Fig. 4b).
Inhibition of WNT/β-catenin signalling by sclerostin can,
besides reducing osteogenic differentiation, also stimulate osteo-
clastogenesis through modulation of the expression of the pro-
osteoclastogenic protein receptor activator of nuclear factor
kappa-B ligand (RANKL) and the RANKL decoy receptor
osteoprotegerin (OPG)13,14. In agreement herewith, mRNA and
protein expression analysis of the osteocyte-enriched bone
fraction of Phd2ot− long bones or IDGIOX2 cells showed a
decrease in RANKL, whereas the expression of OPG was
increased, resulting in a decreased ratio of RANKL/OPG
(Fig. 4c–e). To link the decrease in RANKL/OPG ratio with
impaired osteoclastogenesis in Phd2ot− mice, we co-cultured
PHD2-deficient IDG-SW3 cells with osteoclast precursors from
wild-type mice and treated them with 1α25-dihydroxyvitamin D3
to stimulate osteoclast formation. Of note, PHD2-deficient IDG-
SW3 cells display similar changes in HIF-1α-SIRT1-sclerostin
signalling as IDGIOX2 cells (Supplementary Fig. 6a-c). PHD2-
deficient IDG-SW3 cells showed a reduced capacity to support
osteoclastogenesis, consistent with the decrease in the RANKL/
OPG ratio (Fig. 4f and Supplementary Fig. 6d, e). The decreased
RANKL/OPG ratio in IDGIOX2 cells was reversed by SIRT1
inhibition and we noted that SIRT1 activation is sufficient to
reduce RANKL/OPG ratio in vehicle-treated cells, an effect that is
rescued by adding sclerostin (Fig. 4e, g). Together, these data
indicate that increased HIF signalling in osteocytes affects
osteogenesis and osteoclastogenesis through a SIRT1-mediated
decrease in sclerostin levels.
Lastly, we questioned whether the high bone mass phenotype
observed in Phd2ot− mice was also attributed to increased SIRT1.
Treatment of mutant mice with EX527 completely blunted the
increase in trabecular bone volume (Fig. 5a, b and Supplementary
Fig. 7a, b), and negatively affected cortical bone mass (Fig. 5a, c).
Mechanistically, bone formation was significantly reduced, as
evidenced by dynamic histomorphometric analysis, serum
osteocalcin levels and Ocn mRNA levels (Fig. 5d–f and
Supplementary Fig. 7c). Moreover, EX527 treatment significantly
increased the number of osteoclasts and Rankl/Opg mRNA levels
in mutant mice (Fig. 5g–i), indicative of increased bone
resorption. These cellular effects were accompanied by high
femoral sclerostin expression and low WNT/β-catenin signalling
without affecting SIRT1 mRNA and protein levels (Fig. 5j–n and
Supplementary Fig. 7d, e), analogous to the in vitro data. In
addition, treatment of wild-type mice with SRT1720 resulted in a
high-bone mass phenotype (Fig. 5a–i and Supplementary
Fig. 7a–c), associated with low sclerostin expression and increased
WNT/β-catenin signalling in bone (Fig. 5j–n and Supplementary
Fig. 7e), thereby confirming our in vitro results and further
supporting the reciprocal relationship between SIRT1 activity and
sclerostin levels.
HIF-1α mediates the changes in SIRT1. The data discussed
above indicate that PHD2 silencing in osteocytes results in acti-
vation of the hypoxia signalling pathway, with increased HIF-1α
but not HIF-2α levels, thereby influencing WNT/β-catenin sig-
nalling. To prove that HIF activation was mediating this effect, we
genetically silenced either HIF-1α or HIF-2α in IOX2-treated
IDG-SW3 cells using shRNA. Knockdown of HIF-1α significantly
reduced SIRT1 levels in IDGIOX2 cells, an effect that was asso-
ciated with increased sclerostin levels (Fig. 6a, b) and impaired
WNT/β-catenin signalling (Fig. 6b–f). In contrast, silencing HIF-
2α in IDGIOX2 cells did not affect SIRT1, sclerostin or WNT/β-
catenin signalling (Fig. 6a–f). Moreover, hypoxic culture
increased, in a HIF-1α-mediated way, osteocytic WNT/β-catenin
signalling through a SIRT1-dependent decrease in sclerostin
expression (Supplementary Fig. 8a–g and Supplementary
Fig. 9a–g), thereby further underscoring the importance of PHD-
mediated oxygen sensing by osteocytes to balance HIF levels.
Phd2ot− mice show an enhanced skeletal angiogenic response.
Enhanced osteogenesis is often coupled with angiogenesis22,24,36,
possibly because the bone anabolic response requires sufficient
supply of nutrients. CD31 immunostaining revealed a higher
number of large blood vessels in the metaphysis and cortex of
Phd2ot- long bones (Fig. 7a–d). Molecularly, mRNA levels of
angiogenic factors like vascular endothelial growth factor (Vegf)
and placental growth factor (Plgf) were upregulated in femurs of
Phd2ot− mice, an effect that was recapitulated in cultured
osteocytes (Fig. 7e). To test the functional significance of this
increased production of angiogenic growth factors, we cultured
human umbilical vein endothelial cells (HUVECs) in IDG-SW3-
conditioned medium (Fig. 7f). Conditioned medium from cells
with increased HIF signalling (IDGIOX2 cells) increased the
proliferation rate and the endothelial cell network formation of
HUVECs compared to conditioned medium from IDGVEH cells
(Fig. 7g–i). These beneficial effects were largely dependent on
VEGF production by the osteocytes, as blocking VEGF signalling
by addition of anti-VEGF164 antibody or recombinant soluble
VEGF receptor 1 (also known as fms-like tyrosine kinase-1 or
sFlt-1) hampered the formation of network-like structures
(Fig. 7h, i). This proangiogenic potential of IDGIOX2 cells was
HIF-dependent and isoform-specific, as silencing of HIF-1α, but
not HIF-2α (Fig. 6a), in these cells reversed the effects on
angiogenic growth factor production and endothelial cell beha-
viour (Fig. 7f–i and Supplementary Fig. 10a, b). Together, these
data show that silencing of PHD2 in osteocytes promotes
angiogenesis, through HIF-1α-dependent production of angio-
genic growth factors.
Given the intimate connection between angiogenesis and
osteogenesis in HIF-driven bone formation, we questioned
whether enhanced SIRT1 signalling affects these processes
accordingly. Treatment of Phd2ot− mice with the SIRT1 inhibitor
EX527 completely blunted the increase in bone mass (Fig. 5a–c),
but did not affect the increase in blood vessel number
(Supplementary Fig. 10c, d). Accordingly, Vegf mRNA levels
remained elevated in femora collected from EX527-treated
mutant mice (Supplementary Fig. 10e), presumably because
HIF-1α signalling was still highly active (Fig. 5j). Similarly,
activation of SIRT1 signalling in wild-type mice using SRT1720
resulted in a high-bone mass phenotype (Fig. 5a–c) without
increasing bone vascularity or changing the production of VEGF
(Supplementary Fig. 10c–e). In conclusion, these results indicate
that enhanced SIRT1-dependent WNT/β-catenin signalling in
Phd2ot− mice is the main driver of the anabolic effect on bone,
which can be uncoupled from angiogenesis.
Phd2ot− mice are protected from osteoporotic bone loss. We
finally tested whether the anabolic and anti-catabolic response in
Phd2ot− mice can diminish bone loss in two osteoporotic models
and whether the HIF-SIRT1-sclerostin pathway is involved. First,
we subjected mice to hindlimb unloading, which reflects disuse-
induced bone loss37 and is characterized mainly by decreased
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Fig. 5 SIRT1 regulates bone mass in Phd2ot− mice. a–c 3D microCT models of the tibial metaphysis (a) and quantification of trabecular bone volume (BV/
TV; b) and cortical thickness (Ct.Th; c) in 8-week-old mice (n= 5 Phd2ot+–8 Phd2ot−). Mice were treated with vehicle, SRT1720 or EX527 for 5 weeks. d, e
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mRNA levels in osteocyte-enriched bone fractions (n= 5 Phd2ot+–8 Phd2ot−). j HIF-1α, Sirtuin 1, non-phosphorylated (non-phospho) β-catenin, Lamin A/C
(nuclear cell extracts), and sclerostin and β-actin immunoblot (whole-cell extracts). Protein extracts are isolated from osteocyte-enriched bone fractions.
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Phd2ot+–8 Phd2ot−). Data are means ± SEM. #p < 0.05 (two-way ANOVA). Scale bars in a and g are 50 µm
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bone formation together with increased bone resorption.
Increased sclerostin levels likely contribute to this type of osteo-
porosis11. Hindlimb unloading through tail suspension of 16-
week-old male Phd2ot+ mice for 4 weeks resulted in marked
trabecular and cortical bone loss (BV/TV: −36%, Ct.Th: −17%;
Fig. 8a–c, Supplementary Fig. 11a, b and Supplementary Table 1).
In contrast, unloaded Phd2ot- mice lost significantly less bone
compared to grounded conditions (BV/TV: −26%, Ct.Th: −10%;
Fig. 8a–c, Supplementary Fig. 11a, b and Supplementary Table 1).
The reduction in bone mass in unloaded mice was caused by
changes in bone formation and resorption in both genotypes, but
was less pronounced in Phd2ot- animals: the bone formation rate
was only moderately decreased in Phd2ot− animals (−65% in
Phd2ot+ vs −26% in Phd2ot−; Fig. 8d–f and Supplementary
Table 1) as were osteocalcin levels, and osteoclast number or
Rankl/Opg ratio were not increased, whereas they were sig-
nificantly upregulated in Phd2ot+ mice (Fig. 8g–i and Supple-
mentary Table 1).
Molecularly, unloading had no manifest effect on HIF-1α
expression in either genotype, whereas SIRT1 mRNA and protein
levels were significantly more decreased in unloaded Phd2ot+
mice than in Phd2ot− mice (mRNA: −62% in Phd2ot+ vs. −28%
in Phd2ot−, protein: −56% in Phd2ot+ vs. −39% in Phd2ot−;
Fig. 8j and Supplementary Fig. 11c). This difference in SIRT1
levels was associated with a significant increase in sclerostin
expression in unloaded Phd2ot+ mice (mRNA: 8-fold, protein:
3.3-fold), but only a mild increase in Phd2ot− animals (mRNA:
3.8-fold, protein: 1.7-fold; Fig. 8j and Supplementary Fig. 11d).
This resulted in impaired WNT/β-catenin signalling in unloaded
Phd2ot+ mice, evidenced by reduced nuclear accumulation of
non-phosphorylated β-catenin and Axin2, Dkk-4, Lef-1 and Tcf-1
transcript levels (Fig. 8j–n and Supplementary Table 1), whereas
WNT/β-catenin signalling remained higher in unloaded Phd2ot−
mice compared to both grounded and unloaded wild-type
animals (Fig. 8k–n and Supplementary Table 1).
In the second model, we studied whether osteocytic PHD2
deletion protects mice from oestrogen deficiency-induced osteo-
porotic bone loss, by performing ovariectomy (OVX) or sham
operation on 10-week-old female mice. Similar to skeletal
unloading, OVX in Phd2ot+ mice resulted in a strong reduction
in bone mass (BV/TV: −55%, Ct.Th: −11%), which was
significantly less pronounced in Phd2ot− animals (BV/TV:
−38%, Ct.Th: −5%; Fig. 9a–c, Supplementary Fig. 12a, b and
Supplementary Table 2). The adverse effect of oestrogen
deficiency on skeletal homoeostasis is mainly caused by an
osteoclast-driven response38 and, accordingly, we observed a
significant increase in the number of osteoclasts after OVX, likely
resulting from the elevated Rankl/Opg ratio (Fig. 9d–f and
Supplementary Table 2). However, osteoclast number and Rankl/
Opg ratio were not or only marginally affected in Phd2ot− mice
after OVX (Fig. 9d–f and Supplementary Table 2). Bone
formation was not differentially changed by ovariectomy between
the genotypes, evidenced by histomorphometric analysis after
calcein labelling and serum osteocalcin levels (Fig. 9g–i and
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Supplementary Table 2). Similar to the effect observed in the
skeletal unloading model, PHD2 deletion in osteocytes prevented
the molecular response of OVX on the HIF-1α-SIRT1-sclerostin-
β-catenin pathway observed in Phd2ot+ mice. Indeed, Phd2ot−
mice showed no effect on HIF-1α, no decrease in SIRT1 mRNA
and protein levels, no increase in sclerostin expression and
persistent WNT/β-catenin signalling (Fig. 9j–n, Supplementary
Fig. 12c, d and Supplementary Table 2).
While the initiation of osteoporosis is angiogenesis-indepen-
dent, accumulating evidence suggests that the local blood supply
or decreased angiogenesis contributes, at least in part, to the bone
loss39,40. In line with these observations, hindlimb unloading or
ovariectomy of wild-type animals resulted in decreased
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angiogenesis and impaired femoral Vegf mRNA expression
(Supplementary Figs. 11e–g and 12e–g). In contrast, unloaded
or ovariectomized Phd2ot− mice did not display changes in
vascularization compared to their respective controls, suggesting
that elevated HIF-1α signalling was sufficient to maintain vascular
density in these models (Supplementary Figs. 11e–g and 12e–g).
Taken together, deletion of PHD2 in osteocytes protects mice
from disuse and oestrogen deficiency-induced bone loss by
preventing osteoclast-mediated bone resorption while sustaining
bone formation and a pro-angiogenic response.
Discussion
Osteocytes are crucial for the maintenance of a healthy skeleton
by coordinating the function of osteoblasts and osteoclasts in
response to hormonal and environmental stimuli, likely including
oxygen fluctuations. Here, we show that the osteocytic oxygen
sensor PHD2 controls postnatal bone homoeostasis by orches-
trating the communication with osteoblasts and osteoclasts,
through SIRT1-dependent epigenetic regulation of sclerostin
expression.
The long lifespan of osteocytes together with their peculiar
location within the bone matrix suggest that oxygen and nutrient
delivery must be well controlled to ensure proper functioning.
Our data indicate that the expression of the oxygen sensor PHD2
is higher in osteocytes compared to other skeletal cell types,
suggesting that osteocytes are perfectly equipped to act as fast
responders to changes in oxygen levels. However, we observed
only few osteocytes with HIF-1α expression in wild-type animals,
even though these cells are reported to reside in a low oxygen
environment16. Likely, these relatively low oxygen levels are still
sufficient to support PHD enzymatic activity, which is in line with
other studies that report a low number of HIF-positive osteocytes
in cortical bone26. On the other hand, PHD2 deletion in osteo-
cytes gives a strong bone anabolic response and this phenotype
clearly indicates that osteocytic oxygen sensing is an important
regulator of bone homoeostasis by avoiding inappropriate HIF
signalling. We want to highlight that deletion of the oxygen
sensor PHD2 during bone development was the cause of
increased HIF signalling and not an acute lack of oxygen. The
active HIF signalling together with the increased vascular supply
of oxygen and nutrients likely explains the bone anabolic effect in
Phd2ot− mice. This response may differ from severe ischaemic or
hypoxic conditions, where nutrient and oxygen supply is limited
and thereby probably cause activation of additional pathways,
besides HIF signalling.
The expression of Sost is regulated by stimuli such as
mechanical forces11,41,42, growth factors43 and hormones44,45.
Our study now clearly identifies the local microenvironment,
involving the sensing of oxygen levels, as an important modifier
of Sost expression. More precisely, HIF-1α stabilization in
osteocytes increases the expression and activity of SIRT1, a
NAD+-dependent HDAC, which can inhibit Sost expression33.
Our in vivo data further underscore the importance of the
HIF-1α-SIRT1-sclerostin connection as inhibition of SIRT1
activity in Phd2ot− mice upregulates Sost levels manifestly and
reverses the high bone mass phenotype, without affecting HIF-1α
levels. These findings, together with similar in vitro observations,
highlight that SIRT1 is downstream of HIF-1α signalling.
Consistent with the known role of sclerostin as inhibitor of
canonical WNT signalling, we observed activation of the WNT/β-
catenin pathway in PHD2-deficient osteocytes, evidenced by (i)
nuclear accumulation of non-phosphorylated β-catenin, (ii)
increased expression of downstream target genes, (iii) increased
osteoblast-mediated bone formation and (iv) decreased osteoclast-
dependent bone resorption through the modulation of RANKL
and OPG. Direct regulation of OPG expression by HIF, as has
recently been described26 is less likely, because the increase in
OPG levels in PHD2-deficient osteocytes is prevented when SIRT
is inhibited. Our in vivo and in vitro findings further indicate that
the molecular mechanism causing increased WNT/β-catenin sig-
nalling in PHD2-deficient osteocytes involves HIF-1α-mediated
activation of SIRT1, which on its turn decreases sclerostin levels.
The direct deacetylation of β-catenin by SIRT1, as was recently
described in mesenchymal stem cells35, is less probable because
activation of β-catenin was reversed by adding recombinant
sclerostin to IOX2-treated osteocytes, whereas SIRT1 levels
remained high. Thus, we propose as model a PHD2—HIF-
1α–SIRT1—sclerostin—WNT/β-catenin connection as response
to changes in HIF levels in osteocytic lacunae.
Concomitant with the enhanced osteogenic response,
osteocyte-specific deletion of PHD2 resulted in highly vascular-
ized long bones, which is in line with the common notion that the
hypoxia signalling pathway is a positive regulator of skeletal mass
and angiogenesis24,46. Originally, increased bone vascular density
has been proposed as the main mechanism responsible for HIF-
mediated effects on bone formation22, but recent reports indicate
that HIF can regulate bone mass independently from changes in
angiogenesis25,26. Our results expand this mechanistic model and
show that PHD2/HIF-1α signalling in osteocytes also controls
bone homoeostasis by orchestrating the communication with
osteoblasts and osteoclasts and simultaneously adapting the vas-
culature, although the anabolic bone response was independent
from the increase in angiogenesis.
The importance of WNT/β-catenin signalling for bone
homoeostasis is underscored by the observation that several
skeletal disorders, including osteoporosis, are associated with
deregulation of this pathway47. Results from our present study
and studies by others indicate that with ageing or after skeletal
unloading or ovariectomy, mice show decreased bone mass due to
reduced bone formation and increased bone resorption, an effect
that is mediated by the manifest increase in osteocytic Sost
expression and concomitant downregulation of WNT/β-catenin
signalling11,48,49. Moreover, antibodies that neutralize sclerostin
have shown their potential as treatment of osteoporotic bone loss
in preclinical models and clinical trials50–52. Here, we
Fig. 7 Deletion of PHD2 in osteocytes stimulates angiogenesis. a, b CD31 immunostaining (a) of the tibial metaphysis with quantification (b) of blood
vessel number and size in 8-week-old mice (n= 8 Phd2ot+–10 Phd2ot−). c, d CD31 immunostaining (c) of the cortical diaphysis of tibiae with quantification
(d) of blood vessel number and size (n= 8 Phd2ot+–10 Phd2ot−). e Vegf and PlgfmRNA levels in femora of 8-week-old mice (n= 8 Phd2ot+–10 Phd2ot−) and
in vehicle (IDGVEH) or IOX2-treated IDG-SW3 (IDGIOX2) cells (n= 3). f Scheme of experimental design. HIF-1α (shH1) or HIF-2α (shH2) were silenced in
IDGIOX2 cells and a scrambled shRNA (shScr) was used as control. Conditioned medium was subsequently used to culture HUVECs in monoculture or in
co-culture with IDG-SW3 cells. g Proliferation of HUVECs in monoculture according to the scheme in f (n= 3). h, i Human CD31 (hCD31) immunostaining
(h) and quantification (i) of hCD31-positive surface in HUVECs co-cultured with IDG-SW3 cells, according to the scheme in f. When indicated, cells were
treated with anti-VEGF164 antibody or recombinant mouse soluble VEGFR-1 (sFlt) (n= 3). Data are means ± SEM. *p < 0.05 vs. Phd2ot+ or IDGVEH,
**p < 0.01 vs. Phd2ot+ or IDGVEH, ***p < 0.01 vs. Phd2ot+ or IDGVEH (Student′s t-test), #p < 0.05 (ANOVA: one-way ANOVA in g; two-way ANOVA in i).
Scale bars in a and c are 100 µm, scale bar in h is 500 µm
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demonstrate that selective deletion of PHD2 in osteocytes
attenuates bone loss after skeletal unloading and ovariectomy, by
preventing the increase in sclerostin levels and thus sustaining a
WNT/β-catenin-driven anabolic response. In support of our
work, administration of the pan-PHD inhibitor dimethylox-
alylglycine rescued OVX-induced bone loss39,40, although the
efficacy of using these pan-PHD inhibitors for long-term treat-
ment regimens has yet to be proven.
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Fig. 8 Phd2ot− mice are protected from disuse-induced bone loss. a–c 3D microCT models of the tibial metaphysis (a) and quantification of trabecular bone
volume (BV/TV) (b) and cortical thickness (Ct.Th) (c) 4 weeks after hindlimb unloading and expressed as a percentage relative to grounded mice (n= 7
Phd2ot+–8 Phd2ot−). d, e Calcein labelling of trabecular mineralizing surfaces (d) with quantification (e) of the bone formation rate (BFR) (n= 7 Phd2ot+–8
Phd2ot−). White arrowheads in d indicate calcein incorporation. f Serum osteocalcin levels (n= 7 Phd2ot+–8 Phd2ot−). g, h TRAP staining (g) of the tibial
metaphysis with quantification (h) of the osteoclast surface per bone surface (Oc.S/B.S) (n= 7 Phd2ot+–8 Phd2ot−). Black arrowheads in g indicate
osteoclasts. i Rankl/Opg mRNA levels in osteocyte-enriched bone fractions (n= 7 Phd2ot+–8 Phd2ot−). j HIF-1α, Sirtuin 1, non-phosphorylated (non-phospho)
β-catenin, Lamin A/C (nuclear cell extracts), and sclerostin and β-actin immunoblot (whole-cell extracts). Protein extracts are isolated from osteocyte-
enriched bone fractions. Results are representative of four experiments. HU is hindlimb unloading. k–n Axin2 (k), Dkk-4 (l), Lef-1 (m) and Tcf-1 (n) mRNA
levels in osteocyte-enriched bone fractions (n= 7 Phd2ot+–8 Phd2ot−). Data are means ± SEM. #p < 0.05 (two-way ANOVA). Scale bars in d and g are 50 µm
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In conclusion, we have demonstrated that genetic ablation of
PHD2 in osteocytes results in accumulation of bone mass by
enhancing bone modelling in young and adult mice and reducing
bone remodelling in aged mice. This high bone mass phenotype is
elicited by a strong osteo-anabolic response associated with
reduced bone resorption (Supplementary Fig. 13). Mechan-
istically, silencing PHD2 activates WNT/β-catenin signalling
through SIRT1-dependent downregulation of sclerostin, thereby
increasing osteoblast number and activity, while decreasing
osteoclastogenesis and bone resorption. The enhanced osteogenic
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response was coupled to increased angiogenesis, caused by HIF-
1α-dependent stimulation of angiogenic growth factor produc-
tion. Moreover, Phd2ot− mice were largely protected from bone
loss caused by immobilization or oestrogen deficiency, by pre-
venting the upregulation of sclerostin that is normally observed in
these conditions. These data suggest that inhibiting PHD2 might
be an appealing strategy to treat osteoporosis.
Methods
Animal models. Osteocyte-specific deletion of PHD2 was obtained by crossing
Phd2fl/fl mice53 (provided by P. Carmeliet) with transgenic mice expressing Cre
recombinase under the control of the Dentin Matrix Protein 1 (Dmp1) gene
promoter54 (Dmp1-Cre+ Phd2fl/fl, referred to as Phd2ot-). Dmp1-Cre- Phd2fl/fl
(referred to as Phd2ot+) littermates were used as control in all experiments; analysis
was performed on 8-week-old male mice unless stated otherwise. All mice were on
a 100% C57BL/6 background. To assess the impact of ageing on bone mass, male
(age: 3 weeks, 8 weeks, 16 weeks, 20 weeks, 50 weeks) and female mice (age:
3 weeks, 8 weeks, 10 weeks, 14 weeks, 50 weeks) were used. SRT1720 (50 mg/kg
body weight; Merck) or EX527 (2 mg/kg body weight; Sigma-Aldrich) was admi-
nistered every other day via intraperitoneal injection from weaning (3 weeks of age)
on until 8 weeks of age. At the time of sacrifice, mice were euthanized, blood was
collected and long bones were dissected for RNA isolation, histology and microCT
analysis. Mice were bred in conventional conditions in our animal housing facility
(Proefdierencentrum Leuven, Belgium). Housing and experimental procedures
were approved by the Institutional Animal Care and Research Advisory Committee
of the KU Leuven (ethical approval number P214/2013).
Hindlimb unloading was achieved in 16-week-old male mice by a previously
described tail suspension model37. Briefly, a flexible iron wire surrounded with
orthopaedic tape was applied laterally along the tail of the mice. The mice were
then positioned in a 40–45° head-down tilt, in order that the hindlimbs were lifted
off the ground but the mice were still able to move around by using their forelimbs.
As a control, pair-fed animals without tail suspension were used. Four weeks after
hindlimb unloading, mice were sacrificed, blood was collected and long bones were
dissected for RNA isolation, histology and microCT analysis.
Ovariectomy (OVX) was performed in 10-week-old female mice. After
anaesthetization (pentobarbital, 60 mg/kg body weight), the left and right ovary
were exposed and removed; in the sham-operated (sham) animals, the ovaries were
exposed but left intact. Four weeks after OVX, mice were sacrificed, blood was
collected and long bones were dissected for RNA isolation, histology and microCT
analysis.
MicroCT. MicroCT analysis of the tibiae was performed ex vivo using the high
resolution SkyScan 1172 system (Bruker; 50 kV, 200 μA, 0.5 mm aluminium filter)
and in vivo using the SkyScan 1076 system (Bruker; 50 kV, 100 µA, 1 mm alumi-
nium filter)55. Serial tomographs, reconstructed from raw data using the cone-
beam reconstruction software (NRecon; Bruker), were used to compute trabecular
and cortical parameters, respectively from the metaphyseal and mid-diaphyseal
area. All measurements were performed according to the guidelines of the
American Society for Bone and Mineral Research56.
Histology and (immuno)histochemical staining. For H&E, tartrate-resistant acid
phosphatase (TRAP), osteoid and CD31 staining, bones were fixed overnight at
4 °C in 2% paraformaldehyde, decalcified for 2 weeks in 0.5 M EDTA pH 7.5, and
embedded in paraffin. Undecalcified bones (Von Kossa, calcein labelling) were
fixed overnight at 4 °C in Burckhart’s solution and embedded in methylmetacrylate
(MMA).
Osteoblast parameters were measured on H&E-stained sections. Briefly, paraffin
sections were stained with haematoxylin (Prosan) for 2 min, followed by staining
with eosin (Richard-Alan) for 5 min. Osteoclasts were visualized on paraffin
sections reacted for TRAP activity57 and counterstained with Light Green SF
Yellowfish (Merck). Osteoid was visualized on MMA sections by Goldner staining.
Briefly, sections were stained with a mixture of 0.1% Ponceau de Xylidine (BDH),
0.1% fuchsine (BDH) and 0.2% Orange G (BDH) and counterstained with Light
Green SF Yellowfish. For analysis of mineralized bone tissue, MMA sections were
stained according to Von Kossa. Here, sections were treated with 5% AgNO3 for 1
h, resulting in silver deposits at sites of calcium incorporation. The staining was
fixed with 5% Na2S2O3 and sections were counterstained with haematoxylin.
Immunohistochemical staining conditions were slightly adapted according to
the antibody used. Generally, paraffin sections were de-waxed, rehydrated,
incubated with Antigen Retrieval Solution (Dako) and washed in TBS. Endogenous
peroxidase activity was blocked by immersing the sections in 0.3% H2O2 in
methanol for 20 min. Unspecific antibody binding was blocked by incubating the
sections in 2% BSA-supplemented TBS for 30 min. Subsequently, sections were
incubated overnight with primary antibody against CD31 (550274, 1/50 dilution;
BD Biosciences), HIF-1α (NB100–449, 1/50 dilution; Bio-Techne), sclerostin
(AF1589, 1/200 dilution; Bio-Techne) or SIRT1 (07-131, 1/25 dilution; Merck). For
visualization through a biotin-mediated reaction (CD31), slides were exposed to
HRP-conjugated streptavidin (PerkinElmer) for 30 min and antibody binding was
envisaged by HRP activity on the colour substrate diaminobenzidine. Afterwards,
slides were counterstained with haematoxylin. For HIF-1α, sclerostin and SIRT1
immunostaining, signal visualization was obtained using appropriate Cy3-labelled
secondary antibodies. Hoechst staining was used to visualize cell nuclei.
Histomorphometry. Histomorphometric analysis of murine long bones was per-
formed on an AxioPlan 2 microscope (Zeiss) with AxioVision software (Zeiss)58.
Measurements were done on three sections, each at least 40 µm apart and data were
presented according to the guidelines of the American Society for Bone and
Mineral Research standardized histomorphometry nomenclature59. Briefly, osteo-
blast and osteocyte number and surface were quantified on H&E-stained sections;
the number of viable osteocytes was determined by calculating the difference
between total and empty lacunae. Osteoid, osteoblast and osteoclast surface were
expressed relatively to the total bone surface. Trabecular bone volume was quan-
tified in the secondary spongiosa of Von Kossa-stained sections. To analyse
dynamic bone parameters, calcein (16 mg/kg body weight; Sigma-Aldrich) was
administered via intraperitoneal injection 4 days and 1 day prior to sacrifice. The
mineralizing surface (MS), mineral apposition rate (MAR) and bone formation rate
(BFR) were quantified on unstained MMA-sections. MAR was quantified as the
mean distance between all double fluorochrome labels, divided by the number of
days between calcein injections. BFR was calculated as MS= (dLS+ sLS/2)/BS,
where dLS and sLS represent the bone surface covered by double (d) and single (s)
calcein labels. Vascular density in the metaphysis was measured on CD31-stained
sections and calculated relative to the total bone surface.
Bone mechanical properties. The biomechanical properties of femurs collected
from 8-week-old male mice were determined by three-point bending analysis on a
Bose ElectroForce 3100 system (Bose). Prior to testing, all bones were kept moist in
gauze swabs soaked in PBS. Femora were loaded to failure in the anterior–posterior
direction with a span length of 7 mm at a constant displacement rate of 0.5 mm/s.
WinTest software was used to collect the load-displacement data at 250 data points
per second for a total of 10 s. Work-to-failure and bone stiffness were determined
from the applied load and displacement data.
Whole blood analysis and serum biochemistry. Whole blood collected at the
time of sacrifice was either directly analysed for quantification of RBC number and
haematocrit levels (University Hospital Leuven, Belgium), or centrifuged (7300 × g
for 8 min) and the serum retained. Serum osteocalcin was measured by an in-house
radioimmunoassay60, serum collagen type I cross-linked C-telopeptide levels were
measured by a RatLaps ELISA kit (Immunodiagnostic Systems) according to the
manufacturer’s instructions.
IDG-SW3 cell culture. IDG-SW3 cells (mycoplasma-tested), kindly provided by
L. Bonewald61, were expanded at permissive conditions (33 °C in nucleoside-
supplemented αMEM with 10% FBS, 100 units/ml penicillin, 50 µg/ml strepto-
mycin and 50 U/ml IFN-γ) on rat-tail collagen type I-coated plates (0.15 mg/ml
collagen in 0.02 M acetic acid)61. IFN-γ was from Thermo Fisher Scientific, rat-tail
collagen type I from BD Biosciences and other reagents were from Gibco. To
inhibit PHDs27, IDG-SW3 cells were treated with 10 µM IOX2 (IDGIOX2; Sigma-
Aldrich) or DMSO (1/5000 dilution; Sigma-Aldrich) as control (vehicle, IDGVEH).
After 48 h, cells were used for further experiments.
For osteogenic differentiation, IDG-SW3 cells were expanded and upon
confluency, medium was switched to osteogenic differentiation medium, consisting
of growth medium supplemented with 50 µg/ml ascorbic acid and 4 mM β-
glycerophosphate (both Sigma-Aldrich) and cultured at 37 °C. After 7 days of
osteogenic induction, when Dmp1 gene expression was upregulated61, cells were
treated with either DMSO (1/5000 dilution) or IOX2 (10 µM). Two days later,
IDGVEH cells were treated with 1 µM SRT1720 and IDGIOX2 cells with 5 µM
EX527, supplemented or not with recombinant human sclerostin (5 ng/ml or 30
ng/ml; Bio-Techne) for the following 5 or 12 days. Finally, proteins were extracted
or mineral deposition was visualized using Alizarin Red, as described before62,63.
To silence HIF-1α or HIF-2α in IDG-SW3 cells, we transduced these cells with a
lentivirus carrying a shRNA against HIF-1α or HIF-2α (shHIF-1α and shHIF-2α,
kindly provided by P. Carmeliet; MOI 10) in the presence of 8 µg/ml polybrene
(Sigma-Aldrich)27,30. A lentivirus carrying a nonsense scrambled shRNA sequence
(shScr) was used as a negative control (MOI 10). After 24 h, virus-containing
medium was changed to normal culture medium and 48 h later, cells and
conditioned medium were used for further experiments. To silence PHD2 in IDG-
SW3 cells using CRISPR-Cas9, we transduced these cells with a lentivirus carrying
a plasmid containing the Cas9 enzyme (lentiCRISPR v2; Addgene) and a sgRNA
against Phd2 (5′-GCCTGGGTAACAAGCAACCA-3′). A nonsense scrambled
sgRNA (5′-GCTGATCTATCGCGGTCGTC-3′) was used as a negative control.
After 24 h, virus-containing medium was changed to normal culture medium and
cells were selected with puromycin (0.3 µg/ml) for 7 days before they were used in
subsequent experiments.
To investigate the interaction of osteocytes with osteoclasts, bone marrow cells
(collected after flushing long bones) were plated overnight in αMEM without
nucleosides containing 10% FCS, 100 units/ml penicillin and 50 µg/ml
streptomycin (all from Gibco). Non-adherent cells were collected and seeded onto
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IDG-SW3 cells (i.e. day 0). Cells were treated with 1α25-dihydroxyvitamin
D3 (10−8 M; Sigma-Aldrich) and medium was replaced after 3 days. At day 7,
TRAP staining was performed and the number of TRAP-positive cells with more
than three nuclei was counted as osteoclasts.
A co-culture system was used to study the interaction of osteocytes and
endothelial cells64. Briefly, IDG-SW3 cells were seeded and 24 h later human
umbilical cord vein endothelial cells (Lonza) were added. Cells were cultured for
7 days in conditioned medium derived from IDGVEH or IDGIOX2 cells after
transduction with shScr, shHIF-1α or shHIF-2α, with or without the addition of
recombinant soluble fms-related tyrosine kinase-1 (sFlt-1; 100 ng/ml; Bio-Techne)
or anti-murine VEGF-164 antibody (αVEGF164; 200 ng/ml; Bio-Techne). After
culture, the endothelial cells were visualized by staining with a mouse-anti-human
CD31 primary antibody (1/1000; Dako) and the TSA Cyanine 3 System
(PerkinElmer).
To assess osteocyte behaviour in hypoxia, IDG-SW3 cells were cultured in 1%
oxygen (hypoxic glove box; Coy Lab Products). Briefly, after 7 days of osteogenic
induction (growth medium supplemented with 50 µg/ml ascorbic acid and 4 mM
β-glycerophosphate; both Sigma-Aldrich), cells were placed in the hypoxic glove
box for 48 h in the presence of DMSO (1/5000 dilution) or EX527 (5 µM).
Alternatively, prior to hypoxic culture, cells were transduced with a lentivirus
carrying a shRNA against HIF-1α or HIF-2α (both MOI 10). A lentivirus carrying a
nonsense scrambled shRNA sequence was used as a negative control (MOI 10).
Primary cell isolation and culture. Periosteal cells were isolated from long bones
of 7–9-week-old male mice64. After dissection of muscle and connective tissue,
epiphyses were embedded in 5% low melting point agarose (Lonza). Subsequently,
periosteal cells were isolated by a twofold collagenase-dispase digest (3 mg/ml
collagenase and 4 mg/ml dispase in αMEM with 2 mM glutaMAXTM−1, con-
taining 100 units/ml penicillin and 50 µg/ml streptomycin; all from Gibco). Cells
obtained after 10 min of digest were discarded. The cells obtained during the
second digest (50 min) were passed through a 70 μm nylon mesh, washed and
directly used for RNA or protein analysis (see below).
For isolation of trabecular osteoblasts and bone marrow cells62, long bones of
7–9-week-old male mice were cleaned thoroughly to remove muscle, connective
tissue and periosteum. Subsequently, bones were incubated in a collagenase-dispase
mixture (3 mg/ml collagenase and 4 mg/ml dispase in αMEM with 2 mM
glutaMAXTM-1, containing 100 units/ml penicillin and 50 µg/ml streptomycin; all
from Gibco) for 20 min at 37 °C to remove remaining periosteal cells. Next,
epiphyses were cut away and bone marrow was flushed out, which was collected
after centrifugation (300 × g for 7 min) and used for subsequent analysis. The
remaining bone was cut into small pieces and trabecular osteoblasts were isolated
by incubating the fragments with the collagenase-dispase mixture for 30 min at
37 °C. Cells were passed through a 70 μm nylon mesh (BD Falcon), washed twice
and used for RNA and protein analysis.
The osteocyte-enriched bone fraction was obtained after removal of the bone
marrow, and sequential collagenase and EDTA digestions of the long bones62.
Tibiae and femurs of 7–9-week-old mice were cleaned to remove muscle and
connective tissue. Subsequently, bones were incubated in 2 mg/ml collagenase (in
αMEM with 2 mM glutaMAXTM-1, containing 100 units/ml penicillin and
50 µg/ml streptomycin; all from Gibco) for 30 min at 37 °C. Epiphyses were cut,
bone marrow was flushed and bone was cut into smaller pieces. These fragments
were incubated in 1 mg/ml collagenase mixture for 40 min at 37 °C and this cell
suspension was discarded. The remaining bone chips were washed with PBS and
incubated for 40 min at 37 °C with 5 mM EDTA in PBS. Cell suspension was again
discarded and the bone fragments were finally incubated with 1 mg/ml collagenase
mixture for 50 min at 37 °C. Cells were collected, passed through a 70 μm nylon
mesh and washed twice. This osteocyte-enriched bone fraction was directly lysed
for RNA and protein analysis.
For in vitro osteoclast formation58, bone marrow cells (collected after flushing
long bones) were plated overnight in αMEM without nucleosides containing 10%
FCS, 100 units/ml penicillin and 50 µg/ml streptomycin (all from Gibco). Non-
adherent cells were collected and plated in αMEM supplemented with 20 ng/ml
macrophage colony-stimulating factor (M-CSF; Bio-Techne) and 100 ng/ml
receptor activator of nuclear factor kappa-B ligand (RANKL; Peprotech) (i.e. day
1). At day 6, the number of TRAP-positive cells with more than three nuclei was
counted as osteoclasts.
Quantitative real-time (qRT)-PCR. RNA isolation and qRT-PCR analysis were
performed as described before27,63. RNA was collected and purified with the
RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. cDNA
was synthesized from 1 µg RNA with reverse transcriptase Superscript II RT
(Thermo Fisher Scientific). Gene expression was analysed by Taqman quantitative
RT-PCR using custom-made primers and probes, or commercial primer sets
(Integrated DNA Technologies, Inc.) as listed in Supplementary Table 3. Expres-
sion levels were normalized relative to the expression of Hprt. For quantification of
gene expression, ΔΔCt method was used.
Protein analysis by western blot. For whole-cell lysates27,63, cells were rinsed with
ice-cold PBS and lysed in a total cell lysis buffer (50mM Tris-HCl pH 8.5, 150 nM
NaCl, 0.1% SDS, 1% NP40, 1% sodium desoxycholate, supplemented with protease
inhibitor mix consisting of 1mM PMSF, 5 µg/ml aprotinine, 5 µg/ml leupeptin and
0.33 µg/ml antipain). Nuclear protein fractions27,63 were prepared by lysing the cells
first in a hypotonic buffer (20mM Hepes pH 7.9, 10mM KCl, 1.5mM MgCl2, 1 mM
EDTA, 0.5% NP40, 1mM DTT, supplemented with 1mM Na3VO4, 20mM NaF and
protease inhibitor mix) for 15min at 4 °C followed by mechanical disruption of the
cell membranes. Nuclei were pelleted from the lysates by centrifugation (17,900 × g for
1 min at 4 °C). The pellet was resuspended in a nuclear extraction buffer (50mM
Hepes pH 7.9, 500mM NaCl, 1% NP40, supplemented with protease inhibitor mix)
and after sonication incubated for 15min at 4 °C. Protein concentrations were
determined with the BCA Protein Assay Reagent (Thermo Fisher Scientific).
Proteins were separated by SDS-PAGE under reducing conditions and transferred
to a nitrocellulose membrane (GE Healthcare). Membranes were blocked with 5% dry
milk or bovine serum albumin (Sigma-Aldrich) in Tris-buffered saline with 0.1%
Tween20 for 60min at room temperature and incubated overnight at 4 °C with
primary antibodies. For detection of PHD2 (NB100–2219, 1/1000 dilution; Bio-
Techne), sclerostin (AF1589, 1/1000 dilution; Bio-Techne), total β-catenin (D10A8, 1/
1000 dilution; Cell Signaling Technology), RANKL (NB100-56388, 1/1000 dilution;
Bio-Techne), OPG (AF459, 1/1000 dilution; Bio-Techne) and β-actin expression
(A5441, 1/10000 dilution; Sigma-Aldrich), whole-cell lysates were used; for HIF-1α
(NB100-105, 1/500 dilution; Bio-Techne), HIF-2α (ab199, 1/500 dilution; Abcam),
SIRT1 (07-131, 1/1000 dilution; Merck), non-phosphorylated β-catenin (D13A1, 1/
1000 dilution; Cell Signaling Technology) and Lamin A/C (sc-376248, 1/5000
dilution; Santa Cruz Biotechnology) detection, nuclear protein extracts were used.
Bound primary antibody was visualized by enhanced chemiluminescence
(PerkinElmer) after incubation with a species-specific HRP-conjugated secondary
antibody (Dako). Uncropped scans are provided in Supplementary Fig. 14.
Cell proliferation. Cell proliferation was measured by 5′-bromo-2′-deoxyuridine
(BrdU) incorporation, added during the last 4 h and detected using the Cell Pro-
liferation Biotrack ELISA system (GE Healthcare). The results were normalized to
the amount of DNA.
Chromatin immunoprecipitation qPCR (ChIP-qPCR) analysis. For ChIP-qPCR
analysis27, IDG-SW3 cells were first expanded and upon confluency, medium was
switched to osteogenic differentiation medium and cells were further cultured at 37
°C. After 7 days of osteogenic induction, cells were treated with either DMSO or
IOX2 (10 µM). Two days later, IDGVEH cells were in addition treated with 1 µM
SRT1720 and IDGIOX2 cells were treated with 5 µM EX527 for the following 5 days.
Cultured cells were fixed using 1% formaldehyde, washed and collected by cen-
trifugation (1000 × g for 5 min at 4 °C). The pellet was resuspended in RIPA buffer
(50 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM EDTA, 1% Triton-X100, 0.5%
sodium deoxycholate, 1% SDS, 1% protease inhibitors), homogenized, incubated
on ice for 10 min and sonicated. The samples were centrifuged (16,000 × g for 10
min at 4 °C) and from the supernatant, shared chromatin was used as input and
immunoprecipitation was performed with anti-SIRT1 antibody (07-131; Merck) or
anti-histone H3 acetyl lysine 9 (H3K9Ac) antibody (39137; Active Motif). After
precipitation using Pierce Protein A/G Magnetic Beads (Thermo Fisher Scientific),
followed by RNA and protein digestion, DNA was purified using Agencourt
AMPure XP (Beckman Coulter) according to the manufacturer’s instructions. RT-
qPCR was performed using SYBR® GreenER™ qPCR SuperMix Universal (Thermo
Fisher Scientific) and primers for specific Sost promoter regions (Supplementary
Table 4).
Statistics. Data are presented as means ± SEM. n values represent the number of
independent experiments performed or the number of individual mice phenotyped.
For each independent in vitro experiment, at least three technical replicates were
analysed. For immunoblots, representative images are shown of at least three
independent experiments using samples from different mice/cell lysates. No sta-
tistical tests were used to pre-determine sample size for in vitro and in vivo studies,
and no data was excluded from this study. No statistical methods were used for
randomization for in vitro and in vivo experiments, but investigators were blinded
to group allocation. Data were analysed by two-sided two-sample Student′s t-test,
and one-way or two-way ANOVA with Tukey–Kramer post-hoc test using the
NCSS statistical software. Variance was similar between tested groups and differ-
ences were considered statistically significant at p < 0.05.
Data availability. All data are available from the corresponding author upon
reasonable request.
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